Position paper ANMCO in collaboration with Italian Alliance for Cardiovascular Rehabilitation and Prevention (ITACARE-P): 'the management of hospital discharge'

Eur Heart J Suppl. 2026 May 7;28(Suppl 6):vi249-vi271. doi: 10.1093/eurheartjsupp/suag055. eCollection 2026 May.ABSTRACTHospital discharge is a pivotal stage in the continuum of care, marking the transition from the acute clinical episode to subsequent therapeutic management. Rather than being a pur

C Carmine Riccio

Official proceeding from the 2025 ITACARE-P National Meeting, Rome, October 21-22 2025: The added value of Cardiovascular Rehabilitation in heart failure management: clinical scenarios and expert opinion from a centres network of the Italian Alliance for Cardiovascular Rehabilitation and Prevention (ITACARE-P)

No abstractInt J Cardiol Cardiovasc Risk Prev. 2026 Feb 5;29:200586. doi: 10.1016/j.ijcrp.2026.200586. eCollection 2026 Jun.NO ABSTRACTPMID:41725681 | PMC:PMC12917390 | DOI:10.1016/j.ijcrp.2026.200586

M Matteo Ruzzolini

From clinical inertia to therapeutic optimization in patients with atherosclerotic cardiovascular disease: A Monte Carlo simulation within the ITACARE-P registry

J Clin Lipidol. 2026 Jan;20(1):21-30. doi: 10.1016/j.jacl.2025.11.010. Epub 2025 Nov 13.ABSTRACTBACKGROUND: Despite the intensive approach recommended by the 2019 European Society of Cardiology/European Atherosclerosis Society guidelines, low-density lipoprotein cholesterol (LDL-C) target attainment

A Andrea Faggiano

ITACARE-P/SIGG/SIGOT/SICGE position paper on elderly cardiac patient referral to cardiac rehabilitation

Int J Cardiol Cardiovasc Risk Prev. 2025 Jul 1;26:200454. doi: 10.1016/j.ijcrp.2025.200454. eCollection 2025 Sep.ABSTRACTThe Italian Association for Cardiovascular Rehabilitation and Prevention (ITACARE-P) together with the Società Italiana di Gerontologia e Geriatria (SIGG); Società Italiana di Ger

F Francesco Giallauria

ANMCO Position paper in collaboration with ITACARE-P: Management of hospital discharge

G Ital Cardiol (Rome). 2025 Jul;26(7):519-539. doi: 10.1714/4522.45226.ABSTRACTHospital discharge is a crucial moment in the continuity of care, acting as a bridge between the acute phase and the treatment pathway that follows. Far from being a simple administrative act, it is a complex process requ

C Carmine Riccio

Impact of Polyvascular Disease on Long-Term Prognosis of Patients with Acute Coronary Syndrome-A Retrospective Cohort Study in Italy

J Clin Med. 2025 Jun 11;14(12):4158. doi: 10.3390/jcm14124158.ABSTRACTBackground: Atherothrombosis is a systemic disease that may affect one or more than one vascular bed. Data on the impact of polyvascular disease (PVD) on the long-term prognosis of patients with coronary artery disease (CAD) are s

G Gian Francesco Mureddu

Therapeutic Inertia in Dyslipidemia Management for Secondary Cardiovascular Prevention: Results from the Italian ITACARE-P Network

J Clin Med. 2025 Jan 14;14(2):493. doi: 10.3390/jcm14020493.ABSTRACTBackground/Objectives: This study assessed the proportion of secondary cardiovascular prevention patients who achieved low-density lipoprotein (LDL) cholesterol targets as per the 2019 ESC/EAS Dyslipidemia Guidelines. We also evalua

A Andrea Faggiano

ITACARE-P/SIGG/SIGOT/SICGE position paper: referral of elderly cardiac patient from geriatrics to cardiac rehabilitation.

Recenti Prog Med. 2024 Nov;115(11):527-537. doi: 10.1701/4365.43591.ABSTRACTCardiac rehabilitation (CR) is Class IA indication in patients after an acute cardiovascular (CV) event, with efficacy confirmed even in elderly or frail CV patients CV and geriatric outcomes. However, rate of referral and a

F Francesco Fattirolli

Position paper ITACARE-P/FADOI on the referral from internal medicine to cardiac rehabilitation: Executive summary and factsheet

Int J Cardiol Cardiovasc Risk Prev. 2024 Apr 30;21:200275. doi: 10.1016/j.ijcrp.2024.200275. eCollection 2024 Jun.ABSTRACTThe Italian Association for Cardiovascular Rehabilitation and Prevention (ITACARE-P) and the Italian Federation of Associations of Hospital Doctors on Internal Medicine (FADOI) r

M Marco Ambrosetti

41Bridging the gender gap in Cardiac Rehabilitation. The first step: The equal opportunities project

Int J Cardiol Cardiovasc Risk Prev. 2024 Apr 27;21:200268. doi: 10.1016/j.ijcrp.2024.200268. eCollection 2024 Jun.ABSTRACTWomen receive similar or greater benefits than men from Cardiac Rehabilitation (CR). However, they are less likely to participate. An integrated and gender-sensitive approach to

E Elisabetta Angelino

Treatment of obesity with liraglutide in cardiovascular prevention: Case series by the "ITACARE-P Light-Heart Lab" working group

No abstractInt J Cardiol Cardiovasc Risk Prev. 2024 Apr 27;21:200272. doi: 10.1016/j.ijcrp.2024.200272. eCollection 2024 Jun.NO ABSTRACTPMID:39118985 | PMC:PMC11305995 | DOI:10.1016/j.ijcrp.2024.200272

F Francesco Maranta

What the ITACARE-P Light-Heart and Sweet-Heart projects have taught us

Int J Cardiol Cardiovasc Risk Prev. 2024 Apr 27;21:200274. doi: 10.1016/j.ijcrp.2024.200274. eCollection 2024 Jun.ABSTRACTSweet Heart and Light Heart represent the first two educational formats of ITACARE-P, a recently established scientific association that joins various professionals with the aim

B Bruno Passaretti

The relative impact of components of high residual risk on the long-term prognosis after AMI

Int J Cardiol Cardiovasc Risk Prev. 2024 Jul 6;22:200310. doi: 10.1016/j.ijcrp.2024.200310. eCollection 2024 Sep.ABSTRACTBACKGROUND: The reduction in long-term mortality after acute myocardial infarction (AMI) is less pronounced than that of in-hospital mortality among patients with AMI complicated

G Gian Francesco Mureddu

Cardiac contractility modulation in patients with heart failure: The added value of cardiac rehabilitation in identification, management, and follow-up

No abstractInt J Cardiol Cardiovasc Risk Prev. 2024 May 16;21:200284. doi: 10.1016/j.ijcrp.2024.200284. eCollection 2024 Jun.NO ABSTRACTPMID:38846680 | PMC:PMC11152971 | DOI:10.1016/j.ijcrp.2024.200284

M Matteo Ruzzolini

ANMCO Position paper in collaboration with ITACARE-P: Cardio-oncology rehabilitation. Are we ready?

G Ital Cardiol (Rome). 2024 Apr;25(4):281-293. doi: 10.1714/4244.42210.ABSTRACTCardio-oncology rehabilitation (CORE) is not only an essential component of cancer rehabilitation, but also a pillar of preventive cardio-oncology. CORE is a comprehensive model based on a multitargeted approach and its e

I Irma Bisceglia

Corrigendum to "ANMCO Position paper in collaboration with ITACARE-P: Anti-ischemic treatment in patients with chronic coronary syndrome" [G Ital Cardiol 2023;24(7):571-580]

No abstractG Ital Cardiol (Rome). 2023 Oct;24(10):849. doi: 10.1714/4100.40987.NO ABSTRACTPMID:37767839 | DOI:10.1714/4100.40987

Management of patients with type 2 diabetes during cardiac prevention and rehabilitation. An expert opinion from the Italian Alliance for Cardiovascular Rehabilitation and Prevention (ITACARE-P)

G Ital Cardiol (Rome). 2023 Oct;24(10):834-843. doi: 10.1714/4100.40985.ABSTRACTPatients with diabetes, regardless of their cardiovascular disease and their index event, are more and more often referred to Cardiac Rehabilitation Units. These patients usually show high or very high cardiovascular ris

M Marco Ambrosetti

Cardiopulmonary exercise testing in cardiac rehabilitation: From the reporting form to structured exercise prescription. A proposal from the Italian alliance for cardiovascular rehabilitation and prevention (Itacare-P)

Int J Cardiol Cardiovasc Risk Prev. 2023 Jun 16;18:200191. doi: 10.1016/j.ijcrp.2023.200191. eCollection 2023 Sep.ABSTRACTThe cardiopulmonary exercise test (CPET) is the gold standard for the diagnostic evaluation of exercise intolerance, as for individualized prescription of structured physical tra

M Matteo Ruzzolini

ANMCO Position paper in collaboration with ITACARE-P: Anti-ischemic treatment in patients with chronic coronary syndrome

G Ital Cardiol (Rome). 2023 Jul;24(7):571-580. doi: 10.1714/4060.40436.ABSTRACTOver the last decade, pharmacological therapies for primary and secondary prevention of chronic coronary syndromes enriched with new agents have been demonstrated to be effective in reducing cardiovascular adverse events.

C Carmine Riccio